Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $367 | $378 | $665 | $628 |
| - Cash | $0 | $55 | $98 | $103 |
| + Debt | $0 | $68 | $30 | $38 |
| Enterprise Value | $367 | $391 | $597 | $563 |
| Revenue | – | $317 | $172 | $188 |
| % Growth | – | 84.6% | -8.7% | – |
| Gross Profit | – | $222 | $129 | $142 |
| % Margin | – | 70% | 75.4% | 75.8% |
| EBITDA | – | $78 | $1 | $30 |
| % Margin | – | 24.5% | 0.5% | 16% |
| Net Income | – | $36 | -$9 | $12 |
| % Margin | – | 11.3% | -5% | 6.4% |
| EPS Diluted | – | 2.73 | -0.66 | 0.87 |
| % Growth | – | 513.6% | -175.9% | – |
| Operating Cash Flow | $31 | $51 | $28 | $49 |
| Capital Expenditures | $0 | -$0 | -$0 | -$1 |
| Free Cash Flow | $31 | $51 | $28 | $49 |